title: Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis.
abstract: Cyclooxygenase-2 inhibitors exhibit the same effectiveness on rheumatic symptoms as nonsteroidal anti-inflammatory drugs, have fewer gastrointestinal side effects, but a higher price. Based on cost and healthcare utilization in Norway, this paper explores what factors are most important for the cost-effectiveness of cyclooxygenase-2 inhibitors and points to patient groups that may be most relevant for prescribing coxibs instead of nonsteroidal anti-inflammatory drugs.
authors.affiliation: Institute of Public Health - Health Economics Research Unit, University of Southern Denmark, Odense, 19 Winsløw Park, DK-5000 Odense C, Denmark. isk@sam.sdu.dk
authors.forename: Ivar Sønbø
authors.initials: IS
authors.lastname: Kristiansen
authors.forename: Tore Kristian
authors.initials: TK
authors.lastname: Kvien